$377 Million is the total value of Opaleye Management Inc.'s 44 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CDXS | CODEXIS INC | $15,624,000 | -29.9% | 1,400,000 | 0.0% | 4.14% | -5.3% | |
EIDX | EIDOS THERAPEUTICS INC | $15,459,000 | -14.6% | 315,550 | 0.0% | 4.10% | +15.3% | |
CCXI | CHEMOCENTRYX INC | $14,529,000 | +4.9% | 361,600 | 0.0% | 3.85% | +41.7% | |
QURE | UNIQURE NV | $9,965,000 | -33.8% | 210,000 | 0.0% | 2.64% | -10.6% | |
ATXI | AVENUE THERAPEUTICS INC | $9,253,000 | -6.9% | 1,035,000 | 0.0% | 2.45% | +25.7% | |
FGEN | FIBROGEN INC | $5,074,000 | -19.0% | 146,000 | 0.0% | 1.34% | +9.4% | |
TCDA | TRICIDA INC | $4,268,000 | -41.6% | 194,000 | 0.0% | 1.13% | -21.1% | |
BLRX | BIOLINERX LTDsponsored adr | $22,000 | -42.1% | 16,667 | 0.0% | 0.01% | -14.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CODEXIS INC | 39 | Q3 2023 | 10.9% |
CHIMERIX INC | 31 | Q3 2022 | 16.4% |
XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
FIBROGEN INC | 26 | Q1 2021 | 6.8% |
BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
AXOGEN INC | 20 | Q4 2019 | 18.7% |
ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-10 |
4 | 2024-04-25 |
4 | 2024-04-24 |
4 | 2024-04-19 |
SC 13G/A | 2024-04-09 |
SC 13G | 2024-04-08 |
4 | 2024-03-28 |
4 | 2024-03-22 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.